{{Rsnum
|rsid=7089580
|Gene=CYP2C9
|Chromosome=10
|position=96705223
|Orientation=plus
|GMAF=0.1423
|Assembly=GRCh37
|GenomeBuild=37.1
|dbSNPBuild=132
|geno1=(A;A)
|geno2=(A;T)
|geno3=(T;T)
}}
{{ population diversity
| geno1=(A;A)
| geno2=(A;T)
| geno3=(T;T)
| CEU | 55.8 | 41.6 | 2.7
| HCB | 96.4 | 3.6 | 0.0
| JPT | 99.1 | 0.9 | 0.0
| YRI | 61.9 | 32.0 | 6.1
| ASW | 71.9 | 22.8 | 5.3
| CHB | 96.4 | 3.6 | 0.0
| CHD | 95.4 | 4.6 | 0.0
| GIH | 73.3 | 23.8 | 3.0
| LWK | 74.5 | 23.6 | 1.8
| MEX | 79.3 | 19.0 | 1.7
| MKK | 68.6 | 29.5 | 1.9
| TSI | 57.8 | 36.3 | 5.9
| HapMapRevision=28
}}{{PMID|21270790|OA=1
}} associations with higher [[warfarin]] dose, namely, VKORC1-8191 ([[rs61162043]], P = 0.0041) and 18786 in CYP2C9 ([[rs7089580]], P = 0.035) independent of the previous associations with these genes

{{PMID Auto
|PMID=22158446
|Title=Association of the GGCX (CAA)16/17 repeat polymorphism with higher warfarin dose requirements in African Americans.
|OA=1
}}

{{on chip | Affy GenomeWide 6}}